tracken
Aktienkurs
167,02
$
+29,38
21,35 %1 M.
+2,26
1,37 %6 M.
-61,77
27,00 %YTD
-180,08
51,88 %1 J.
+145,44
673,91 %3 J.
+152,97
1.088,59 %5 J.
+152,97
1.088,59 %10 J.
Nasdaq,
Schlusskurs Mi, 30.11.2022
Powered by
ISIN
US09075V1026
Symbol
BNTX
Index
Sektor
Industrie
Kennzahlen
| Marktkapitalisierung | 40,53 Mrd. USD |
| Enterprise Value | 27,65 Mrd. USD |
| KGV (TTM) KGV | 3,57 |
| EV/FCF (TTM) EV/FCF | 2,12 |
| EV/Sales (TTM) EV/Sales | 1,36 |
| KUV (TTM) KUV | 1,99 |
| KBV (TTM) KBV | 2,25 |
| Dividendenrendite | 0,00 % |
| Letzte Dividende (FY21) | 2,13 USD |
Mehr anzeigen
Finanzdaten von BioNTech SE - ADR
| Sep. '22 |
+/-
%
|
||
| Umsatz | 20.361 20.361 |
24 %
24 %
|
|
| Bruttoertrag | 16.671 16.671 |
22 %
22 %
|
|
| EBITDA | 14.801 14.801 |
20 %
20 %
|
EBIT (Operatives Ergebnis) EBIT | 14.671 14.671 |
20 %
20 %
|
| Nettogewinn | 11.345 11.345 |
27 %
27 %
|
|
Angaben in Millionen USD.
BioNTech SE - ADR Aktie News
GlobeNewsWire
ein Tag alt
|
Neutral
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
MAINZ, Germany and KRAKOW, Poland – November 30, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU, “Ryvu”), a clinical-stage company developing oncology therapeutics today announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreem...
MAINZ, Germany and KRAKOW, Poland – November 30, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU, “Ryvu”), a clinical-stage company developing oncology therapeutics today announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreem...
Forbes
13 Tage alt
|
Positiv
New Pfizer-BioNTech Covid Vaccine Is More Effective Than The Original, Study Shows
Pfizer-BioNTech's new bivalent Covid-19 vaccine—which targets the original strain and some Omicron subvariants—provides more protection against the virus and its omicron variants than its initial vaccine, according to a study released Friday.
Pfizer-BioNTech's new bivalent Covid-19 vaccine—which targets the original strain and some Omicron subvariants—provides more protection against the virus and its omicron variants than its initial vaccine, according to a study released Friday.
Market Watch
13 Tage alt
|
Positiv
Pfizer and BioNTech updated booster shows strong results against new omicron sublineages in fresh analysis of data
A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and German partner BioNTech said Friday.
A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and German partner BioNTech said Friday.
| Hauptsitz | Deutschland |
| CEO | Ugur Sahin |
| Mitarbeiter | 3.082 |
| Gegründet | 2008 |
| Webseite | www.biontech.de |
aktien.guide Premium
Mit dem Premium Zugang erhältst Du sämtliche Funktionen von aktien.guide uneingeschränkt mit Realtime-Kursen für 6.931 weltweite Aktien - auf komplett werbefreien Seiten.
* bei jährlicher Zahlung